Linaclotide — Dose Evidence | Peptides Community

Reference only — not a dosing recommendation.

Approved regimen

Approved labeled regimen

Product-, indication-, and jurisdiction-specific — see the monograph

IBS-C (adults): 290 mcg PO once daily on empty stomach (US, EU). CIC (adults): 145 mcg PO once daily (US, 72 mcg available for tolerability). Pediatric FC (2–17 yr): 72 mcg PO once daily (US) — approved since 2023 for functional constipation from age 2. Pediatric IBS-C (7–17 yr): 145 mcg PO once daily (US) — approved since 2024 from age 7. Capsules may be opened and mixed with applesauce or liquid for administration.

Studied in trials

Studied regimens (not recommendations)

Studied in trials — not a recommended dose

290 mcg dose studied for both IBS-C and CIC (higher diarrhea rate in CIC studies).

Not established

What is not established

Use in opioid-induced constipation.
Long-term efficacy >1 year in controlled settings.
No established or recommended human dose for any other indication.

Linaclotide — section dose et administration de la monographie